Diabetes

Omnipod 5 is an automated, tubeless insulin dispensing system that allows for continuous infusion and bolus dosing as needed.

A new study warns that fluoroquinolone could increase the risk of altered mental status and hospitalizations for advanced chronic kidney disease patients, though it is rare.

Study finds link between higher insulin doses and the risk of developing cancer in patients with type 1 diabetes.

Meta-analysis of randomized controlled trials adds to growing evidence around certain antihypertensive drug classes showing promise for primary or secondary prevention of diabetes.

American Diabetes Association updates recommendations regarding SGLT-2 inhibitors, GLP-1 RA, and finerenone for cardiovascular and renal comorbidities.

Phentermine and Topiramate ER (Qsymia) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management.

Patients with diabetes on Medicare Advantage were also less likely to be prescribed newer, more expensive medicine than patients on Medicare Fee-For-Service plans, indicating potential disparities in care.

The FDA approved tirzepatide for the treatment of type 2 diabetes on May 13, 2022

The objective of this study is to evaluate the use of low-dose pioglitazone, without relying on high doses of insulin, by enhancing sensitivity as a suitable, cost-effective strategy compared to larger insulin doses in patients with limited access to care.

Liraglutide (Saxenda) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with type 2 diabetes.

Saxagliptin (Onglyza) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Study results show that there is a link between leaving the television on, night lights, and smart phones and higher disease rates.

The American Diabetes Association guidelines have self-care and lifestyle recommendations for patients and health care professionals.

Lifestyle modifications are the cornerstone of treatment.

These clear-cut guidelines help pharmacists making sure the patients are getting the right drug to set them up for success and prevent problems down the road.

The future trend in managing diabetes will extend into glycemic control, weight reduction, and renal liver, for example.

In February of this year, the new statistics came out where we're at now 37 million with diabetes and 96 million with prediabetes.

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

Semaglutide (Wegovy) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients.

Stephanie Mason believes that pharmacists should expect their involvement in glycemic management to increase in the near future.

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Appropriate screening tools can help identify individuals at increased risk for or with anxiety, depression, and eating disorders.

Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 to lower blood glucose levels.

Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.

Kombiglyze is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.